Imatinib Torrent Pharma (Uk) (Imatinib)

Imatinib selectively binds to the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways that promote cell division and survival, thereby reducing the proliferation of cancer cells that depend on these kinases.

The dosage of Imatinib Torrent Pharma is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should determine the appropriate regimen.

The safety of Imatinib during pregnancy or lactation has not been established. It is generally advised to avoid use unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Consultation with a specialist obstetrician‑oncologist is essential before exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first approved BCR‑ABL inhibitor and remains a standard first‑line therapy for chronic phase CML. Newer agents such as dasatinib and nilotinib offer alternative potency and side‑effect profiles, but Imatinib’s long‑term safety data and cost‑effectiveness make it a widely used option.

Imatinib Torrent Pharma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Imatinib Torrent Pharma is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks include hepatotoxicity, severe neutropenia, cardiac dysfunction such as left ventricular failure, and rare cases of pulmonary hypertension. Patients should be monitored regularly for liver enzymes, blood counts and cardiac function to detect these complications early.

Imatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inducers or inhibitors without appropriate dose adjustments.